Certain pesticides linked to kidney cancer in agricultural workers
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2020/7/papers/kidney-cancer/thumb894915.jpg?itok=fVpzjugS" /><br /><p>New findings from the Agricultural Health Study suggest exposure to certain pesticides may increase risk of renal cell carcinoma.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
Fighting Liver Cancer Takes Big Financial Toll: Study
THURSDAY, Feb. 2, 2023 -- Out-of-pocket costs can leave Medicare patients with the most common type of liver cancer in financial distress.
While Medicare payments in the first year after diagnosis with hepatocellular carcinoma (HCC) exceeded... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 2, 2023 Category: General Medicine Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
New Imaging Score May Predict Chemo Benefit in Early OPSCC New Imaging Score May Predict Chemo Benefit in Early OPSCC
If validated, this scoring system could help identify patients with oropharyngeal squamous cell carcinoma who can skip chemo. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
